Patent Law Weblog
recent posts
- Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
about
Category: International IP
-
By Jason Derry — The Thailand government recently announced that it has issued two more compulsory licenses for generic versions of patented drugs. One of the drugs is Plavix, a heart disease drug made by Bristol-Myers Squibb and Sanofi-Aventis. The other drug is Kaletra, an HIV/AIDS drug made by Abbott Laboratories. The licenses follow…
-
By Jason Derry — As discussed by Gareth Dixon and Jacinta Flattery-O'Brien of Shelston IP, a bill has been passed by Australia's Federal Parliament that allows otherwise infringing activities to be carried out for the purposes of obtaining regulatory approval. The bill allows generic companies to obtain approval for products during the patent term…
-
By Kevin Noonan — On December 19th, the European Patent Office decided to revoke European Patent EP 0 652 872, owned by AstraZeneca for its blockbuster drug Nexium® ("the little purple pill"). This action was undertaken by German generic drug manufacturer, Ratiopharm International GmbH, and was unexpected in light of Ratiopharm's earlier failure…
-
By Christopher P. Singer — In a December 19, 2006 press release, Pfizer Inc. announced that its Australian patent AU 601,981 covering atorvastatin (the active ingredient in Lipitor®) was upheld by the Australian Federal Court in Victoria. The ruling concluded Ranbaxy's 2005 lawsuit and imposes an injunction against Ranbaxy's generic product. The 601,981…
-
By Mark Chael — AstraZeneca's European Patent No. EP 0 652 872 related to Nexium® was reviewed on December 19, 2006 by the Boards of Appeal at the European Patent Office. In 2003, this patent successfully survived an opposition filed by Ratiopharm GmbH of Germany. However, appeal no. T0401/04 was received on March…
-
By Jason Derry — As we reported on December 6, the Thailand government recently issued a compulsory license on Merck's AIDS drug, Efavirenz. We also noted that Merck was not happy about the action because Thailand failed to contact Merck prior to making the decision. Today, the Intellectual Property Owners Association (IPO) reported…
-
By Jason Derry — The public health ministry in Thailand has officially announced that it will permit Thailand's public drug maker, the Government Pharmaceutical Organization, to manufacture a generic version of Merck's AIDS drug, Efavirenz, for a 5 year period. The compulsory license was made by the acting Thai military government, who declared…
Patent Docs 